Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 21;225(8):1399–1410. doi: 10.1093/infdis/jiaa121

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 3. — Humoral responses induced by HB-101 vaccination in healthy subjects. Antihuman cytomegalovirus glycoprotein B (gB) immunoglobulin (Ig)G (A), cytomegalovirus-neutralizing Abs (nAbs) (B), lymphocytic choriomeningitis virus (LCMV) nAbs (C), and correlation analysis of serum gB-binding and cytomegalovirus nAbs in vaccine recipients versus naturally infected individuals (D). Arrows indicate time of vaccine administration. Shown are geometric mean titers (GMTs) and 95% confidence intervals (CI). The GMTs of gB IgG and cytomegalovirus nAbs in naturally cytomegalovirus-infected donors were 3960 and 226, respectively (N = 40). For LCMV nAbs, 30 seronegative samples used as specificity controls had a titer <8 (detection limit), whereas 1 positive control donor with documented history of past LCMV infection had a titer of 88. Kruskal-Wallis’ test was used to compare the GMTs in the placebo and vaccine groups at Month 4 (*, P < .0001). Two-by-two comparisons indicated significant differences (P < .0001; Mann-Whitney’s test) between each vaccine dose group and placebo. Intragroup comparisons between Day 0 and all the other time points up to Month 4 revealed statistically significant differences (P < .0001; Friedman’s test) for the 3 vaccine doses in both gB-specific IgG titers and cytomegalovirus nAbs. Percentages of responders at Week 16 are illustrated on the right side of each response (A–C). Responders were those with measurements above the assay-specific cutoffs defining seropositivity (dashed line: [A] 74 arbitrary enzyme-linked immunosorbent assay units [AEU]/mL for anti-gB IgG, <8 for cytomegalovirus nAbs and LCMV nAbs). Samples with undetectable seroreactivity were arbitrarily assigned a value corresponding to 50% of the assay’s detection limit (A and B). Spearman’s test was used for correlation analysis, r = 0.92. NT, neutralizing titer.